Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study - Report - MDSpire

Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study

  • By

  • Hong jian Ren

  • Qi lin Ren

  • Zhi juan Zhang

  • Jun jie Lei

  • Ning Xu

  • May 4, 2026

  • 0 min

Share

Clinical Report: Radiotherapy and Immunotherapy in Elderly ESCC Patients

Overview

This study evaluates the combination of radiotherapy and immunotherapy in elderly patients with esophageal squamous cell carcinoma (ESCC), revealing improved overall survival compared to radiotherapy alone. The findings highlight the importance of comorbidity assessment in treatment planning.

Background

Esophageal carcinoma is a highly aggressive malignancy, particularly affecting older adults who often have multiple comorbidities that complicate treatment. The integration of immunotherapy with traditional therapies like radiotherapy has shown promise in enhancing survival outcomes. However, elderly patients are underrepresented in clinical trials, necessitating real-world studies to validate treatment strategies.

Data Highlights

{'confidence_intervals': True}

Key Findings

{'safety_profile_details': True}

Clinical Implications

The findings suggest that combining immunotherapy with radiotherapy may improve survival in elderly ESCC patients, particularly those with moderate comorbidity. Clinicians should consider the CIRS-G score when evaluating treatment options for this population.

Conclusion

The integration of immunotherapy into radiotherapy regimens shows promise for enhancing survival in elderly patients with ESCC. Further validation in larger studies is necessary to confirm these exploratory findings.

References

  1. Frontiers in Oncology, 2026 -- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
  2. The ASCO Post, 2025 -- Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
  3. The ASCO Post, 2026 -- Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
  4. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma - PMC, 2024
  5. the asco post — Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
  6. Frontiers | Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma
  7. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma - PMC
  8. Frontiers | First-line immune checkpoint inhibitors in older adults (≥75 years) with advanced esophageal squamous cell carcinoma: efficacy and safety

Original Source(s)

Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study

  • by Hong jian Ren, Qi lin Ren, Zhi juan Zhang, Jun jie Lei, Ning Xu

  • May 4, 2026

Related Content

Dual-energy and perfusion CT for predicting response to chemo-radiotherapy in head and neck cancer: an exploratory study

Case Report: A seventy-year-stable chest wall bronchogenic cyst with sudden enlargement: coincidence or connection with a concurrent thymic carcinoma?

First Patient Treated with Proton Therapy at Lynn Cancer Institute

The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.

  • by

  • May 15, 2026

  • 5 min